Seronegative Myasthenia Gravis - Efgartigimod IV

Clinical trial NCT06587867 · RECRUITING

Trial details

NCT number: NCT06587867
Sponsor: University Health Network, Toronto
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Efgartigimod Generalized Myasthenia Gravis

Start date: 2023-06-01
Primary completion: 2025-05-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.